Adaptimmune Therapeutics plc
Hedge Funds Holdings
Last updated:
Adaptimmune Therapeutics plc‘s stocks are currently a part of 76 hedge funds’ portfolios, which represents 11.77% of the total amount of its stocks outstanding. This makes up a total of 110.05M shares of Adaptimmune Therapeutics plc. Compared to the previous quarter, the number fell by -3.02% or -3.42M shares fewer. As for the holding position changes, 32.89% (25) of current hedge fund investors increased the number of shares held, 30.26% (23) of current holders sold a part of the shares held, and 21.05% (16) closed the holdings completely. 12 hedge funds are new holders of Adaptimmune Therapeutics plc stock in Q1 2022, it is 15.79% of total holders.
Hedge funds holding Adaptimmune Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 54 |
|---|---|
| Q3 2017 | 65 |
| Q4 2017 | 69 |
| Q1 2018 | 75 |
| Q2 2018 | 85 |
| Q3 2018 | 92 |
| Q4 2018 | 77 |
| Q1 2019 | 65 |
| Q2 2019 | 56 |
| Q3 2019 | 43 |
| Q4 2019 | 37 |
| Q1 2020 | 46 |
| Q2 2020 | 77 |
| Q3 2020 | 78 |
| Q4 2020 | 87 |
| Q1 2021 | 83 |
| Q2 2021 | 79 |
| Q3 2021 | 89 |
| Q4 2021 | 82 |
| Q1 2022 | 76 |
Hedge funds changes in Adaptimmune Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 11 | 11 | 13 | 5 | 14 |
|---|---|---|---|---|---|
| Q3 2017 | 18 | 21 | 13 | 6 | 7 |
| Q4 2017 | 14 | 20 | 17 | 10 | 8 |
| Q1 2018 | 18 | 25 | 19 | 12 | 1 |
| Q2 2018 | 22 | 20 | 25 | 12 | 6 |
| Q3 2018 | 18 | 18 | 36 | 11 | 9 |
| Q4 2018 | 13 | 27 | 23 | 28 | -14 |
| Q1 2019 | 7 | 22 | 16 | 19 | 1 |
| Q2 2019 | 3 | 14 | 19 | 11 | 9 |
| Q3 2019 | 3 | 11 | 12 | 16 | 1 |
| Q4 2019 | 9 | 7 | 8 | 15 | -2 |
| Q1 2020 | 17 | 12 | 10 | 8 | -1 |
| Q2 2020 | 41 | 18 | 10 | 10 | -2 |
| Q3 2020 | 22 | 23 | 19 | 20 | -6 |
| Q4 2020 | 29 | 26 | 18 | 20 | -6 |
| Q1 2021 | 14 | 28 | 21 | 16 | 4 |
| Q2 2021 | 9 | 25 | 21 | 13 | 11 |
| Q3 2021 | 18 | 30 | 20 | 7 | 14 |
| Q4 2021 | 13 | 17 | 33 | 19 | 0 |
| Q1 2022 | 12 | 25 | 23 | 16 | 0 |
Hedge funds changes in Adaptimmune Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 1,000 | 0 |
|---|---|---|
| Q3 2017 | 88,000 | 0 |
| Q4 2017 | 158,000 | 108,000 |
| Q1 2018 | 721,000 | 983,000 |
| Q2 2018 | 2,083,000 | 654,000 |
| Q3 2018 | 10,297,000 | 2,557,000 |
| Q4 2018 | 2,251,000 | 136,000 |
| Q1 2019 | 6,000 | 41,000 |
| Q2 2019 | 85,000 | 0 |
| Q3 2019 | 29,000 | 0 |
| Q4 2019 | 0 | 0 |
| Q1 2020 | 168,000 | 95,000 |
| Q2 2020 | 5,464,000 | 10,689,000 |
| Q3 2020 | 2,023,000 | 1,038,000 |
| Q4 2020 | 1,230,000 | 767,000 |
| Q1 2021 | 982,000 | 1,108,000 |
| Q2 2021 | 692,000 | 691,000 |
| Q3 2021 | 2,489,000 | 1,958,000 |
| Q4 2021 | 725,000 | 429,000 |
| Q1 2022 | 191,000 | 299,000 |